The burgeoning field of metabolic disease management is witnessing a novel convergence of therapies. Tirzepatide , a dual GIP/GLP-1 receptor activator , alongside Retatrutide , a triple GIP/GLP-1/GCG receptor https://lucycxw603734.theideasblog.com/42283168/retatrutide-and-nicotinamide-adenine-dinucleotide-a-combined-strategy-to-metabolic-health